Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryFeb282014	Fate Therapeutics Observes Rare Disease Day 2014 SAN DIEGO, Feb. 28, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, is joining the Muscular Dystrophy Association (MDA) and other advocacy organizations Read All »	View HTML Fate Therapeutics Observes Rare Disease Day 2014 14.2 KB
Toggle SummaryFeb272014	Fate Therapeutics to Present at Upcoming March Conferences SAN DIEGO , Feb. 27, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer , M.D., M.A.S., President and Chief Executive Read All »	View HTML Fate Therapeutics to Present at Upcoming March Conferences 17.2 KB
Toggle SummaryFeb262014	Fate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment From Its Phase 1b Study of PROHEMA(R) SAN DIEGO, Feb. 26, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today the release of new data on the observed effects of ex vivo pharmacologic Read All »	View HTML Fate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment From Its Phase 1b Study of PROHEMA(R) 17.8 KB
Toggle SummaryNov132013	Fate Therapeutics Reports Third Quarter 2013 Financial Results Cleared Key Milestones for Resumption of ProHema Phase 2 Clinical Trial Selected Wnt7a Protein Analogs for Advancement into IND-Enabling Activities Extended Breadth of Patent Protection for HSC Modulation Platform SAN DIEGO, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All »	View HTML Fate Therapeutics Reports Third Quarter 2013 Financial Results 28.6 KB
Toggle SummaryNov062013	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2013 Financial Results on November 13, 2013 SAN DIEGO, Nov. 6, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2013 Financial Results on November 13, 2013 10 KB
Toggle SummaryOct042013	Fate Therapeutics Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares SAN DIEGO, Oct. 4, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced the closing of its previously announced initial public offering of Read All »	View HTML Fate Therapeutics Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares 11.1 KB
Toggle SummaryOct022013	Fate Therapeutics to Present at World Muscle Society Congress SAN DIEGO, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that its Senior Vice President, Early Program Development, Dr. Read All »	View HTML Fate Therapeutics to Present at World Muscle Society Congress 13.8 KB
Toggle SummaryOct012013	Fate Therapeutics, Inc. Announces Pricing of Initial Public Offering SAN DIEGO, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced the pricing of its initial public offering of 6,666,667 shares of its Read All »	View HTML Fate Therapeutics, Inc. Announces Pricing of Initial Public Offering 10.5 KB
Toggle SummaryAug202013	Fate Therapeutics Files Registration Statement for Proposed Initial Public Offering San Diego, CA – Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to Read All »	View HTML Fate Therapeutics Files Registration Statement for Proposed Initial Public Offering 11.2 KB
Toggle SummaryApr222013	Fate Therapeutics Presents Efficacy Data for WNT7a-Analog Program at Muscular Dystrophy Association 2013 Scientific Conference San Diego, CA – Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today the presentation of preclinical data from its WNT7a protein analog program for the treatment of muscular dystrophy at the Read All »	View HTML Fate Therapeutics Presents Efficacy Data for WNT7a-Analog Program at Muscular Dystrophy Association 2013 Scientific Conference 14 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.